Table 1.
Summary of ICI metagenome studies
| Study | Study name utilized in this study | Accession number | N# | N* | Cancer type included | Treatment | Clinical outcomes | Country$ |
|---|---|---|---|---|---|---|---|---|
| Frankel et al., Neoplasia 2017 | FrankelAE_2017 | PRJNA397906 | 39 | 39 | Melanoma | CTLA4/PD-1 blockade | Response | USA |
| McCulloch et al.,Nature Medicine. 2022 | McCullochJA_2022 | PRJNA762360 | 62 | 62 | Melanoma | PD-1 blockade | Response/irAEs/OS/PFS | USA |
| Spencer et al.,Science 2021 | SpencerCN_2021 | PRJNA770295 | 167 | 155 | Melanoma | PD-1 blockade | Response/PFS | USA |
| Peters et al., Genome Medicine 2019 | PetersBA_2019 | PRJNA541981 | 48 | 23 | Melanoma | CTLA4/PD-1 blockade | OS/PFS | USA |
| Lee et al.Nature Medcine.2022 | LeeKA_2022 | PRJEB43119 | 164 | 162 | Melanoma | CTLA4/PD-1 blockade | Response/PFS12 | UK |
| Routy et al., Science 2018 | RoutyB_2018 | PRJEB22863 | 219 | 219 | NSCLC; RCC | PD-1 blockade | Response | France |
| Derosa et al.Nature Medcine.2022 | DerosaL_2022 | PRJNA751792 | 338 | 336 | NSCLC | PD-1 blockade | Response/OS | France/Canada |
OS overall survival, PFS progression-free survival, NSCLC non-small-cell lung cancer, RCC renal cell carcinoma, PFS12 whether PFS longer than 12 months, irAEs immune-related adverse events.
# Sample size in the original paper.
*Samples collected pretreated with ICIs and with matched clinical and metagenome data available which utilized in this study, the filter process listed in Fig. S1.
$ The country in which the study was recruited.